Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of L-Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Norepinephrine SCHEMBL29460319 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL29371849 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL2610 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL29399946 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2609 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL2429869 | 1.00 | TDP1 (1.00) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL4155242 | 0.98 | BLM (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL10576062 | 0.98 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| Norepinephrine SCHEMBL3334108 | 0.98 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 | |
| L-Norepinephrine SCHEMBL17504429 | 0.98 | TDP1 (0.96) | TDP1KDM4EBLMMAPTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069612-A1 | Terpenoids and cannabinoids, which are naturally extracted from stressed plants, support the microbiome for the gastrointestinal-central nervous-immune system's homeostasis and cure addiction to opioid, cannabinoid, cocaine, and self-drug dependence through safe and effective pharmacological, neurobiological, and psychological remodeling mechanisms of the brain's reward centers. | RAHME MARC (CA) | 2026-03-12 | — | — | US | disclosed |
| CN-119757509-A | Application of cyclodextrin in analysis of catecholamine molecular isomers and analysis method | 常州华班亚生物科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| WO-2016048155-A1 | MEDICAL COMPOSITION | DSM IP ASSETS B.V. (NL) | 2016-03-31 | — | — | WO | disclosed |
| US-7723065-B2 | Conditions for reactions mediated by yeast | VICTORIA UNIVERSITY (AU) | 2010-05-25 | — | — | US | disclosed |
| US-7723065-B2 | Conditions for reactions mediated by yeast | VICTORIA UNIVERSITY (AU) | 2010-05-25 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
| US-20100068771-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED BETA-AMINO ALCOLHOLS STARTING FROM GLYCINE AND AN ALDEHYDE IN THE PRESENCE OF A THREONINE ALDOLASE AND A DECARBOXYLASE | DSM IP ASSETS B.V. (NL) | 2010-03-18 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
| US-20040053355-A1 | Modular approach to on-line synthesis, drug discovery and biochemical transformations using immobilized enzyme reactors | MCGILL UNIVERSITY (CA) | 2004-03-18 | — | — | US | disclosed |
| EP-1290133-A1 | MODULAR APPROACH TO ON-LINE SYNTHESIS, DRUG DISCOVERY AND BIOCHEMICAL TRANSFORMATIONS USING IMMOBILIZED ENZYME REACTORS | McGill University (CA) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090298-A1 | MODULAR APPROACH TO ON-LINE SYNTHESIS, DRUG DISCOVERY AND BIOCHEMICAL TRANSFORMATIONS USING IMMOBILIZED ENZYME REACTORS | MCGILL UNIVERSITY (CA) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB3, ADRB1, ADRA1D | ADRB2 4/4885ADRB1 2/4885ADRA2A 10/4885 |
| US-20260069612-A1 | Terpenoids and cannabinoids, which are naturally extracted from stressed plants, support the microbiome for the gastrointestinal-central nervous-immune system's homeostasis and cure addiction to opioid, cannabinoid, cocaine, and self-drug dependence through safe and effective pharmacological, neurobiological, and psychological remodeling mechanisms of the brain's reward centers. | OPRK1, CNR1, CNR2 | ADRB2 110/4885ADRB1 93/4885ADRA2A 78/4885 |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | SLC6A2, VEGFA, COMT | ADRB2 7/4885ADRB1 4/4885ADRA2A 28/4885 |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB2, ADRB1, SLC6A2 | ADRB2 1/4885ADRB1 2/4885ADRA2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.